These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 22038777)

  • 1. Human pluripotent stem cells for disease modelling and drug screening.
    Maury Y; Gauthier M; Peschanski M; Martinat C
    Bioessays; 2012 Jan; 34(1):61-71. PubMed ID: 22038777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human pluripotent stem cells for genetic disease modeling and drug screening.
    Gauthier M; Maury Y; Peschanski M; Martinat C
    Regen Med; 2011 Sep; 6(5):607-22. PubMed ID: 21916596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An introduction to induced pluripotent stem cells.
    Hanley J; Rastegarlari G; Nathwani AC
    Br J Haematol; 2010 Oct; 151(1):16-24. PubMed ID: 20666774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro generation of megakaryocytes and platelets from human embryonic stem cells and induced pluripotent stem cells.
    Takayama N; Eto K
    Methods Mol Biol; 2012; 788():205-17. PubMed ID: 22130710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cells for drug screening.
    Laposa RR
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):240-5. PubMed ID: 21499120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concise review: Embryonic stem cells versus induced pluripotent stem cells: the game is on.
    Puri MC; Nagy A
    Stem Cells; 2012 Jan; 30(1):10-4. PubMed ID: 22102565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current applications of human pluripotent stem cells: possibilities and challenges.
    Ho PJ; Yen ML; Yet SF; Yen BL
    Cell Transplant; 2012; 21(5):801-14. PubMed ID: 22449556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. iPSC technology: platform for drug discovery. Point.
    Ellis J; Bhatia M
    Clin Pharmacol Ther; 2011 May; 89(5):639-41. PubMed ID: 21512521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening.
    Song M; Paul S; Lim H; Dayem AA; Cho SG
    Arch Pharm Res; 2012 Feb; 35(2):245-60. PubMed ID: 22370779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of induced pluripotent stem cells in drug development.
    Inoue H; Yamanaka S
    Clin Pharmacol Ther; 2011 May; 89(5):655-61. PubMed ID: 21430656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of induced pluripotent stem cell technology.
    Zhou H; Ding S
    Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of human embryonic stem cells in drug discovery. Counterpoint.
    Esteso P; Gearhart JD
    Clin Pharmacol Ther; 2011 May; 89(5):641-3. PubMed ID: 21512522
    [No Abstract]   [Full Text] [Related]  

  • 13. Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases.
    Lian Q; Chow Y; Esteban MA; Pei D; Tse HF
    Thromb Haemost; 2010 Jul; 104(1):39-44. PubMed ID: 20539907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Converting human pluripotent stem cells to neural tissue and neurons to model neurodegeneration.
    Chambers SM; Mica Y; Studer L; Tomishima MJ
    Methods Mol Biol; 2011; 793():87-97. PubMed ID: 21913095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells.
    Mehta A; Chung YY; Ng A; Iskandar F; Atan S; Wei H; Dusting G; Sun W; Wong P; Shim W
    Cardiovasc Res; 2011 Sep; 91(4):577-86. PubMed ID: 21565833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial reprogramming of human somatic cells to generate pluripotent stem cells: a possible alternative to the controversial use of human embryonic stem cells.
    Romano G
    Drug News Perspect; 2008 Oct; 21(8):440-5. PubMed ID: 19034350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery.
    Steel D; Hyllner J; Sartipy P
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):133-40. PubMed ID: 19152222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ID1 and ID3 represent conserved negative regulators of human embryonic and induced pluripotent stem cell hematopoiesis.
    Hong SH; Lee JH; Lee JB; Ji J; Bhatia M
    J Cell Sci; 2011 May; 124(Pt 9):1445-52. PubMed ID: 21486943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concise review: alchemy of biology: generating desired cell types from abundant and accessible cells.
    Pournasr B; Khaloughi K; Salekdeh GH; Totonchi M; Shahbazi E; Baharvand H
    Stem Cells; 2011 Dec; 29(12):1933-41. PubMed ID: 21997905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro models of pancreatic differentiation using embryonic stem or induced pluripotent stem cells.
    Higuchi Y; Shiraki N; Kume S
    Congenit Anom (Kyoto); 2011 Mar; 51(1):21-5. PubMed ID: 21129040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.